SHANGHAI JUNSHI BIO YC1 (8SJ) - Total Liabilities
Based on the latest financial reports, SHANGHAI JUNSHI BIO YC1 (8SJ) has total liabilities worth €6.33 Billion EUR (≈ $7.40 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SHANGHAI JUNSHI BIO YC1 (8SJ) equity growth momentum to track the company's year-over-year net asset growth rate.
SHANGHAI JUNSHI BIO YC1 - Total Liabilities Trend (2021–2025)
This chart illustrates how SHANGHAI JUNSHI BIO YC1's total liabilities have evolved over time, based on quarterly financial data.
SHANGHAI JUNSHI BIO YC1 Competitors by Total Liabilities
The table below lists competitors of SHANGHAI JUNSHI BIO YC1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dexus Convenience Retail REIT
AU:DXC
|
Australia | AU$248.27 Million |
|
TPI POLENE POWER
BK:TPIPP-R
|
Thailand | ฿31.03 Billion |
|
Northpointe Bancshares, Inc.
NYSE:NPB
|
USA | $6.81 Billion |
|
HANSEN TECHNOLOGIES LTD.
F:H2T
|
Germany | €221.29 Million |
|
Shanghai Golden Bridge
SHG:603918
|
China | CN¥319.78 Million |
|
Henan Huaying Agricultural Development Co Ltd
SHE:002321
|
China | CN¥2.51 Billion |
|
Peapack-Gladstone Financial
NASDAQ:PGC
|
USA | $6.87 Billion |
|
Civista Bancshares Inc
NASDAQ:CIVB
|
USA | $3.79 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SHANGHAI JUNSHI BIO YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 8SJ company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SHANGHAI JUNSHI BIO YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SHANGHAI JUNSHI BIO YC1 (2021–2025)
The table below shows the annual total liabilities of SHANGHAI JUNSHI BIO YC1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €6.33 Billion ≈ $7.40 Billion |
+30.43% |
| 2024-12-31 | €4.85 Billion ≈ $5.67 Billion |
+20.57% |
| 2023-12-31 | €4.02 Billion ≈ $4.70 Billion |
+44.58% |
| 2022-12-31 | €2.78 Billion ≈ $3.25 Billion |
+2.34% |
| 2021-12-31 | €2.72 Billion ≈ $3.18 Billion |
-- |
About SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more